Central Research Laboratories, Hokko Chemical Industry, Co., Ltd, Toda, Atsugi 243-0023, Japan.
Carbohydr Res. 2013 Mar 7;368:8-15. doi: 10.1016/j.carres.2012.12.010. Epub 2012 Dec 19.
Described are the efficient syntheses of β-galactose-type unsaturated carbasugar amine, N-octyl-4-epi-β-valienamine (1a, NOEV) and 6-deoxy NOEV (12), starting from (+)-proto-quercitol (2), which is readily provided by the bioconversion of myo-inositol. NOEV is a potent chemical chaperone drug candidate for G(M1)-gangliosidosis. An intermediate alkadiene benzoate was prepared from 2 in five steps, with the key step being a Wittig reaction with an enol ester. The 6-deoxy derivative 12 was conveniently synthesized from the versatile intermediate dibromo compound 6, which was also an intermediate in the synthesis of NOEV. Enzyme inhibition assays demonstrated that 12 possessed stronger inhibitory activity than the parent 1a, suggesting that the C-6 position of the 4-epi-β-valienamine-type inhibitor could have hydrophobic interactions at the β-galactosidase active site residues.
描述了β-半乳糖型不饱和碳环糖胺,N-辛基-4-差向-β-紫堇醇胺(1a,NOEV)和 6-去氧-NOEV(12)的高效合成方法,以(+)-原奎尼丁(2)为起始原料,(+)-原奎尼丁(2)可通过肌醇的生物转化轻易获得。NOEV 是 G(M1)-神经节苷脂贮积病的有效化学伴侣药物候选物。中间体烷二烯苯甲酸酯由 2 经五步制备,关键步骤是与烯醇酯的Wittig 反应。6-去氧衍生物 12 可从多功能中间体二溴化合物 6 方便地合成,6 也是 NOEV 合成的中间体。酶抑制试验表明,12 比母体 1a 具有更强的抑制活性,这表明 4-差向-β-紫堇醇胺型抑制剂的 C-6 位可能在β-半乳糖苷酶活性部位残基处具有疏水相互作用。